N-acetylcysteine Use and Risk of Age-Related Macular Degeneration in a Large United States Cohort
In a large, matched retrospective cohort study of US adults aged 50 and older, sustained N-acetylcysteine use was not found to be associated with a reduced short-term incidence of age-related macular degeneration.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human eye contains a tiny, critical patch of tissue at the back called the macula, which acts as the high-definition center of our vision. As people age, this area can slowly deteriorate, a condition known as age-related macular degeneration. This process is often driven by a buildup of damage inside the cells, similar to how metal rusts when exposed to air and moisture over time. Scientists call this damage oxidative stress, and it is a major reason why the cells in the retina stop working correctly and eventually die. Because of this link, researchers have long wondered if taking supplements that act as "rust removers" for the body could help prevent or slow down this vision loss. One such supplement is N-acetylcysteine, a substance that helps the body produce its own natural defenses against this cellular damage. While laboratory studies and animal experiments have shown that this supplement can protect eye cells, it remained unclear whether taking it as a daily pill actually helps real people in the real world.
A team of researchers set out to answer this question by looking at a massive collection of health records from people across the United States. They focused on a diverse group of adults over the age of fifty, examining whether those who had taken N-acetylcysteine for a sustained period were less likely to develop age-related macular degeneration compared to those who had not. To ensure a fair comparison, the scientists carefully matched each person who took the supplement with another person of the same age, sex, and background who did not. They defined "sustained use" as taking the supplement for at least ninety-one days in a row, a timeframe they believed was long enough to see if the body was truly benefiting from the treatment. The study tracked these individuals for about six months to see if new cases of the eye disease appeared.
The results of this large-scale investigation were clear and unexpected. Despite the strong biological reasons to believe the supplement would work, the researchers found no evidence that taking N-acetylcysteine reduced the risk of developing age-related macular degeneration in this group. In fact, the data suggested that people who took the supplement were not any less likely to develop the condition than those who did not. The study included nearly six hundred matched pairs of participants, and among them, only a small number developed the disease during the observation period. When the scientists analyzed the numbers, the risk for the supplement users was actually slightly higher, though the difference was not large enough to be considered statistically significant. This means the study could not prove the supplement was harmful, but it also could not prove it was helpful.
The researchers considered several reasons why their findings differed from a previous study conducted in Taiwan, which had suggested a strong protective benefit. In that earlier study, the supplement was prescribed by doctors for specific lung conditions, meaning patients likely took consistent, high doses under medical supervision. In the United States, however, this substance is mostly sold over the counter as a dietary supplement. People who buy it this way might take varying amounts, skip doses, or use different strengths, making it difficult for the body to get a steady, therapeutic level of the drug. Additionally, the study relied on electronic health records to track who took the supplement. If a person bought the supplement at a store but did not tell their doctor, or if the doctor did not write it down in the medical record, the study would count them as someone who never took it. This kind of missing information tends to hide any real benefits a treatment might have, making it look like the treatment does nothing at all.
Ultimately, this study does not disprove the idea that N-acetylcysteine could protect the eyes in a biological sense, but it does show that the way people currently use it in the United States does not appear to prevent the disease. The researchers concluded that the supplement, as it is commonly used today, does not offer a meaningful shield against age-related vision loss. They noted that the study was limited by its short duration and the difficulty of tracking over-the-counter use accurately. To truly know if this substance can save sight, future research would need to follow patients for much longer, use precise measurements of how much they take, and confirm eye health with detailed imaging rather than just medical codes. For now, the evidence suggests that simply adding this supplement to a daily routine is not a proven strategy for keeping eyes healthy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.